Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial

Author:

Gupta Neil,Manirambona Linda,Shumbusho Fabienne,Kabihizi Jules,Murangwa Anthere,Serumondo Janvier,Makuza Jean Damascene,Nsanzimana Sabin,Muvunyi Claude Mambo,Mukabatsinda Constance,Musabeyezu Emmanuel,Camus Gregory,Grant Philip M,Kateera Fredrick

Funder

Gilead Sciences

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference41 articles.

1. Global progress report on HIV, viral hepatitis and sexually transmitted infections 2021. Accountability for the global health sector strategies, 2016–2021: actions for impact,2021

2. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017;Smith;JHEP Rep,2019

3. HCV market intelligence report 2021 and preliminary HBV market insights,2021

4. Achieving a high cure rate with direct-acting antivirals for chronic hepatitis C virus infection in Cameroon: a multi-clinic demonstration project;Coyer;Trop Med Int Health,2020

5. Treatment of hepatitis C genotypes 1 to 5 in sub-Saharan Africa using direct-acting antivirals;Sultan;Am J Trop Med Hyg,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3